Acepodia is a clinical-stage biotechnology company developing accessible cancer cell therapies using its Antibody-Cell Conjugation (ACC) technology. By linking tumor-targeting antibodies to immune effector cells like gamma delta T cells and NK cells, Acepodia’s ACE therapies offer enhanced tumor targeting, with potential to treat a broad range of solid tumors and hematologic cancers.
